“We believe Amgen’s focus and ability to incorporate our genetic research into their research and development efforts will translate our discoveries into meaningful therapies for patients.” DeCODE targeted the 275,000 Icelanders because they are so homogenous, meaning that genetic anomalies will stand out much more clearly than in a melting pot like the United States. High-throughput proteomics platforms measuring thousands of proteins in blood combined with genomic information have the power to bridge the gap between the genome and diseases and in that capture some of the environmental contributions to their risk and pathogenesis. Med., founder and CEO at deCODE Genetics.
#AMGEN DECODE GENETICS FULL#
“One of the ways to truly realize the full value of human genetics, is to make our research synergistic with drug development efforts where target discovery, validation and prioritization efforts can be accelerated,” said Kari Stefansson, M.D., Dr. Using its unique expertise and access to a well-defined population in Iceland, deCODE Genetics has discovered genetic risk factors for dozens of diseases ranging from cardiovascular disease to cancer. This fits perfectly with our objective to pursue rapid development of relevant molecules that reach the right disease targets while avoiding investments in programs based on less well-validated targets.”įounded in 1996, deCODE Genetics is a global leader in analyzing and understanding the link between the genome and disease susceptibility. Reykjavk, Iceland, J Scientists at deCODE genetics a subsidiary of Amgen together with collaborators from Denmark report on the whole genome sequences of 150 thousand participants in the UK biobank in a paper published in the journal Nature today. today announced a collaboration that brings together SomaLogic's expertise in human proteins with deCODE's expertise in human genetics. 13, 2018 /PRNewswire/ - deCODE genetics, an Amgen subsidiary, and SomaLogic, Inc. “This capability will enhance our efforts to identify and validate human disease targets. REYKJAVIK, Iceland and BOULDER, Colo., Dec. “deCODE Genetics has built a world-class capability in the study of the genetics of human disease,” said Robert A. The all-cash transaction values deCODE Genetics at $415 million, subject to customary closing adjustments, and was unanimously approved by the Amgen Board of Directors. First report from the world’s most ambitious sequencing project. 10, 2012 /PRNewswire/ - Amgen (NASDAQ:AMGN) and deCODE Genetics today announced that the companies have entered into a definitive agreement under which Amgen will acquire deCODE Genetics, a global leader in human genetics, headquartered in Reykjavik, Iceland.
DeCODE Genetics Will Provide Amgen With an Industry-Leading Ability to Identify and Validate Disease Targets in Human Populations
0 kommentar(er)
